Dr. Sharman Part 2 of the Interview on Prognos... - CLL Support

CLL Support

23,088 members39,648 posts

Dr. Sharman Part 2 of the Interview on Prognostic Factors

bkoffman profile image
bkoffmanCLL CURE Hero
4 Replies

My blog: bkoffman.blogspot.com sports the second part of the interview with Dr. Sharman, plus my discussion of predictive versus prognostic markers, and some bad news.

Written by
bkoffman profile image
bkoffman
CLL CURE Hero
To view profiles and participate in discussions please or .
4 Replies
AussieNeil profile image
AussieNeilPartnerAdministrator

Very interesting to hear what Dr Sharman considers useful tests which starts at 2:40. Seems Zap-70 has had its day.

Mikey47 profile image
Mikey47

Thanks Brian. It's frustrating hearing about these new markers while there is no testing for them at present. I asked my consultant if I was likely to get tested for BIRC3 or SF3B1 while on the RESONATE2 Imbruvica study but it seems there are no plans to.

I tend to think that if BIRC3 is as bad as p17/p53, I would know it by now if I had it after nearly 4 years with the 11q.

bkoffman profile image
bkoffmanCLL CURE Hero

It is frustrating, but may be moot with the new meds. Still unclear.

Mikey47 profile image
Mikey47

Sorry to hear about the loss of your 2 friends.

Not what you're looking for?

You may also like...

Dr Jeff Sharman on Nutritional Supplements

For one of most balanced and informative postings I've read on nutritional supplements and how they...

Part 2 of ASH Interview with Dr. Sharman, a patient meeting in Seattle and off to iwCLL later tonight

Friends, This week on the CLL Society website, in our Conference coverage section, we share the...

FCR may CURE some of us - Dr Sharman

"In today's CLL climate, web informed patients are rebelling against FCR - and in many cases, I...

ASH 2012 Interview: Dr Jeff Sharman "Why New CLL Treatments Supersede FCR"

Dr Sharman's blog http://www.cll-nhl.com, is well worth keeping an eye on for pertinent but easily...

Dr Sharman on "Choosing first therapy in CLL"

Dr. Sharman briefly discusses the whys of the rather unique Watch and Wait 'treatment' decision for...